SCHEMBL6726003

SCHEMBL6726003

NS(=O)(=O)c1ccc(-c2ncccc2-c2ccc(OC(F)(F)F)cc2)cc1F

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGS2 P35354 5/20 0.41
TRPV1 Q8NER1 2/20 0.41
SCN9A Q15858 1/20 0.40
CBFB Q13951 1/20 0.39
ABL1 P00519 3/20 0.39
BCR P11274 2/20 0.39
ENPP2 Q13822 1/20 0.38
ALOX5AP P20292 4/20 0.38
FEN1 P39748 4/20 0.38
PTGS1 P23219 3/20 0.38
F2 P00734 1/20 0.37
F10 P00742 1/20 0.37
PRSS1 P07477 1/20 0.37
PRSS2 P07478 1/20 0.37
PRSS3 P35030 1/20 0.37
KDM4E B2RXH2 1/20 0.37
NPC1 O15118 1/20 0.37
ALDH1A1 P00352 1/20 0.37
GAA P10253 1/20 0.37
MAPT P10636 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6722623 0.90 PTGES2 (0.44) TRPV1SCN9AALOX5APFEN1
SCHEMBL7544751 0.89 PTGS2 (0.45) PTGS2TRPV1SCN9ACBFBABL1
SCHEMBL6743053 0.88 PTGS2 (0.41) PTGS2TRPV1SCN9ACBFBABL1
SCHEMBL6746673 0.88 PTGS2 (0.42) PTGS2TRPV1SCN9ACBFBABL1
SCHEMBL6723930 0.85 ALOX5AP (0.47) PTGS2TRPV1ALOX5APFEN1PTGS1
SCHEMBL6718496 0.85 PTGS2 (0.52) PTGS2ALOX5APFEN1PTGS1F2
SCHEMBL6723428 0.85 PTGS2 (0.50) PTGS2ALOX5APFEN1PTGS1F2
SCHEMBL6723491 0.84 PTGS1 (0.39) PTGS2SCN9AALOX5APFEN1PTGS1
SCHEMBL7046168 0.84 PTGS1 (0.40) PTGS2TRPV1SCN9AALOX5APFEN1
SCHEMBL6723314 0.83 FEN1 (0.43) PTGS2ALOX5APFEN1PTGS1F2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040092552-A1 2-Fluorobenzenesulfonyl compounds for the treatment of inflammation PHARMACIA CORPORATION 2004-05-13 US disclosed
EP-1296971-A2 2-FLUOROBENZENESULFONYL COMPOUNDS FOR THE TREATMENT OF INFLAMMATION Pharmacia Corporation (US) 2003-04-02 EP disclosed
US-20020183362-A1 2-Fluorobenzenesulfonyl compounds for the treatment of inflammation PHARMACIA CORPORATION 2002-12-05 US disclosed
WO-2001081332-A2 2-FLUOROBENZENESULFONYL COMPOUNDS FOR THE TREATMENT OF INFLAMMATION PHARMACIA CORPORATION (US) 2001-11-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020183362-A1 2-Fluorobenzenesulfonyl compounds for the treatment of inflammation FPR2, FPR1, PTGES2 PTGS2 5/4885TRPV1 1395/4885SCN9A 4442/4885
US-20040092552-A1 2-Fluorobenzenesulfonyl compounds for the treatment of inflammation FPR2, PTGES2, FPR1 PTGS2 5/4885TRPV1 1347/4885SCN9A 4401/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.